Immunovant Net Debt vs Total Current Liabilities Analysis

IMVT Stock

USD 28.20 0.53 1.84%

Immunovant financial indicator trend analysis is infinitely more than just investigating Immunovant recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunovant is a good investment. Please check the relationship between Immunovant Net Debt and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Net Debt vs Total Current Liabilities

Net Debt vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunovant Net Debt account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.

The correlation between Immunovant's Net Debt and Total Current Liabilities is -0.92. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Immunovant, assuming nothing else is changed. The correlation between historical values of Immunovant's Net Debt and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Immunovant are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Net Debt i.e., Immunovant's Net Debt and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Current Liabilities

Total Current Liabilities is an item on Immunovant balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunovant are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Immunovant's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 496.4 M in 2024, despite the fact that Enterprise Value Multiple is likely to grow to (5.03).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	156.0M	208.3M	282.7M	150.5M
Research Development	101.8M	160.3M	212.9M	118.3M

Total Operating Expenses Research Development

Immunovant fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.9	1.0	0.91	0.63	0.92	0.98	0.91	1.0	0.28	0.89	0.62	-0.94	-1.0	-0.95	0.96	0.6	0.83	0.96	0.43	0.93	-0.03	0.92	0.81	-0.89	0.96
Total Current Liabilities	0.9		0.9	0.94	0.69	0.98	0.89	1.0	0.9	0.35	0.97	0.61	-0.91	-0.92	-0.88	0.95	0.59	0.9	0.95	0.49	0.98	0.05	0.98	0.88	-0.88	0.95
Total Stockholder Equity	1.0	0.9		0.9	0.62	0.92	0.98	0.9	1.0	0.28	0.88	0.62	-0.94	-1.0	-0.95	0.96	0.6	0.82	0.96	0.43	0.93	-0.03	0.92	0.8	-0.88	0.96
Net Tangible Assets	0.91	0.94	0.9		0.7	0.97	0.84	0.95	0.91	0.52	0.88	0.83	-0.98	-0.92	-0.79	0.97	0.82	0.91	0.97	0.46	0.97	0.03	0.97	0.78	-0.9	0.97
Accounts Payable	0.63	0.69	0.62	0.7		0.61	0.54	0.69	0.63	0.3	0.51	0.56	-0.62	-0.64	-0.48	0.68	0.55	0.54	0.68	0.95	0.61	-0.05	0.62	0.28	-0.53	0.67
Common Stock Shares Outstanding	0.92	0.98	0.92	0.97	0.61		0.9	0.98	0.92	0.4	0.97	0.69	-0.96	-0.94	-0.88	0.98	0.67	0.92	0.98	0.37	1.0	0.04	1.0	0.9	-0.91	0.98
Other Stockholder Equity	0.98	0.89	0.98	0.84	0.54	0.9		0.89	0.98	0.15	0.91	0.49	-0.89	-0.98	-0.99	0.92	0.46	0.78	0.92	0.36	0.9	-0.06	0.9	0.85	-0.85	0.92
Total Liab	0.91	1.0	0.9	0.95	0.69	0.98	0.89		0.91	0.37	0.97	0.63	-0.92	-0.92	-0.88	0.96	0.62	0.91	0.96	0.49	0.98	0.05	0.99	0.88	-0.89	0.96
Total Current Assets	1.0	0.9	1.0	0.91	0.63	0.92	0.98	0.91		0.27	0.89	0.61	-0.94	-1.0	-0.95	0.96	0.59	0.83	0.96	0.43	0.93	-0.03	0.92	0.81	-0.89	0.96
Short Long Term Debt Total	0.28	0.35	0.28	0.52	0.3	0.4	0.15	0.37	0.27		0.29	0.72	-0.45	-0.29	-0.05	0.38	0.75	0.66	0.38	0.14	0.44	0.67	0.36	0.15	-0.63	0.37
Other Current Liab	0.89	0.97	0.88	0.88	0.51	0.97	0.91	0.97	0.89	0.29		0.51	-0.89	-0.9	-0.92	0.92	0.5	0.89	0.92	0.29	0.96	0.08	0.97	0.96	-0.88	0.92
Property Plant And Equipment Net	0.62	0.61	0.62	0.83	0.56	0.69	0.49	0.63	0.61	0.72	0.51		-0.82	-0.64	-0.38	0.71	1.0	0.68	0.71	0.3	0.7	0.0	0.68	0.4	-0.68	0.71
Current Deferred Revenue	-0.94	-0.91	-0.94	-0.98	-0.62	-0.96	-0.89	-0.92	-0.94	-0.45	-0.89	-0.82		0.95	0.84	-0.96	-0.8	-0.87	-0.96	-0.36	-0.96	0.05	-0.95	-0.81	0.9	-0.96
Net Debt	-1.0	-0.92	-1.0	-0.92	-0.64	-0.94	-0.98	-0.92	-1.0	-0.29	-0.9	-0.64	0.95		0.94	-0.97	-0.62	-0.84	-0.97	-0.44	-0.94	0.03	-0.94	-0.81	0.89	-0.97
Retained Earnings	-0.95	-0.88	-0.95	-0.79	-0.48	-0.88	-0.99	-0.88	-0.95	-0.05	-0.92	-0.38	0.84	0.94		-0.89	-0.36	-0.75	-0.89	-0.31	-0.88	0.08	-0.89	-0.9	0.8	-0.89
Cash	0.96	0.95	0.96	0.97	0.68	0.98	0.92	0.96	0.96	0.38	0.92	0.71	-0.96	-0.97	-0.89		0.69	0.9	1.0	0.46	0.98	0.0	0.98	0.83	-0.89	1.0
Non Current Assets Total	0.6	0.59	0.6	0.82	0.55	0.67	0.46	0.62	0.59	0.75	0.5	1.0	-0.8	-0.62	-0.36	0.69		0.69	0.69	0.3	0.69	0.04	0.66	0.39	-0.68	0.69
Non Currrent Assets Other	0.83	0.9	0.82	0.91	0.54	0.92	0.78	0.91	0.83	0.66	0.89	0.68	-0.87	-0.84	-0.75	0.9	0.69		0.9	0.32	0.94	0.4	0.9	0.8	-0.97	0.9
Cash And Short Term Investments	0.96	0.95	0.96	0.97	0.68	0.98	0.92	0.96	0.96	0.38	0.92	0.71	-0.96	-0.97	-0.89	1.0	0.69	0.9		0.46	0.98	0.0	0.98	0.83	-0.89	1.0
Net Receivables	0.43	0.49	0.43	0.46	0.95	0.37	0.36	0.49	0.43	0.14	0.29	0.3	-0.36	-0.44	-0.31	0.46	0.3	0.32	0.46		0.37	-0.03	0.39	0.06	-0.32	0.45
Common Stock Total Equity	0.93	0.98	0.93	0.97	0.61	1.0	0.9	0.98	0.93	0.44	0.96	0.7	-0.96	-0.94	-0.88	0.98	0.69	0.94	0.98	0.37		0.09	0.99	0.89	-0.93	0.98
Non Current Liabilities Total	-0.03	0.05	-0.03	0.03	-0.05	0.04	-0.06	0.05	-0.03	0.67	0.08	0.0	0.05	0.03	0.08	0.0	0.04	0.4	0.0	-0.03	0.09		-0.01	0.0	-0.38	-0.01
Capital Surpluse	0.92	0.98	0.92	0.97	0.62	1.0	0.9	0.99	0.92	0.36	0.97	0.68	-0.95	-0.94	-0.89	0.98	0.66	0.9	0.98	0.39	0.99	-0.01		0.91	-0.88	0.98
Other Current Assets	0.81	0.88	0.8	0.78	0.28	0.9	0.85	0.88	0.81	0.15	0.96	0.4	-0.81	-0.81	-0.9	0.83	0.39	0.8	0.83	0.06	0.89	0.0	0.91		-0.78	0.83
Deferred Long Term Liab	-0.89	-0.88	-0.88	-0.9	-0.53	-0.91	-0.85	-0.89	-0.89	-0.63	-0.88	-0.68	0.9	0.89	0.8	-0.89	-0.68	-0.97	-0.89	-0.32	-0.93	-0.38	-0.88	-0.78		-0.89
Net Invested Capital	0.96	0.95	0.96	0.97	0.67	0.98	0.92	0.96	0.96	0.37	0.92	0.71	-0.96	-0.97	-0.89	1.0	0.69	0.9	1.0	0.45	0.98	-0.01	0.98	0.83	-0.89

Click cells to compare fundamentals

Immunovant Account Relationship Matchups

Immunovant fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	109.4M	412.5M	515.6M	405.8M	666.4M	699.7M
Total Current Liabilities	15.3M	18.8M	44.5M	43.3M	48.6M	27.1M
Total Stockholder Equity	94.1M	391.5M	469.8M	362.5M	617.8M	648.6M
Net Tangible Assets	94.1M	391.5M	469.8M	362.5M	416.9M	242.7M
Accounts Payable	1.2M	2.4M	18.6M	1.4M	7.2M	5.0M
Common Stock Shares Outstanding	43.2M	87.8M	109.7M	123.1M	138.1M	80.8M
Other Stockholder Equity	185.3M	590.4M	824.8M	928.0M	1.4B	1.5B
Total Liab	15.3M	21.0M	45.7M	43.3M	48.6M	27.7M
Total Current Assets	109.1M	409.0M	512.9M	404.3M	665.8M	699.1M
Short Long Term Debt Total	3.2M	3.4M	2.4M	1.2M	138K	131.1K
Other Current Liab	14.1M	14.0M	24.7M	40.8M	41.2M	24.7M
Property Plant And Equipment Net	65K	3.5M	2.6M	1.5M	595K	565.3K
Net Debt	(97.4M)	(396.7M)	(491.5M)	(375.3M)	(635.2M)	(603.5M)
Retained Earnings	(91.2M)	(198.7M)	(355.4M)	(566.3M)	(825.7M)	(784.4M)
Cash	100.6M	400.1M	493.8M	376.5M	635.4M	367.9M
Non Current Assets Total	311K	3.5M	2.6M	1.5M	595K	565.3K
Cash And Short Term Investments	100.6M	400.1M	493.8M	376.5M	635.4M	367.9M
Net Receivables	3.0M	1.1M	12.9M	885K	5.5M	4.8M
Common Stock Total Equity	5K	10K	12K	13K	15.0K	8.9K
Liabilities And Stockholders Equity	109.4M	412.5M	515.6M	405.8M	666.4M	386.8M
Non Current Liabilities Total	14.1M	2.2M	1.2M	47K	347K	329.7K
Capital Surpluse	185.3M	590.4M	824.8M	928.0M	1.1B	556.3M
Other Current Assets	5.5M	7.7M	6.3M	26.9M	24.9M	13.1M
Net Invested Capital	94.1M	391.5M	469.8M	362.5M	617.8M	354.9M
Capital Stock	5K	10K	12K	13K	14K	10.0K
Net Working Capital	93.8M	390.2M	468.4M	361.0M	617.2M	353.9M
Short Term Debt	3.2M	2.4M	1.1M	1.2M	276K	262.2K
Common Stock	5K	10K	12K	13K	14K	10.0K
Property Plant Equipment	65K	201K	330K	333K	383.0K	216.3K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC